FDA Grants Frontline Eltrombopag Priority Review for Severe Aplastic Anemia

May 30, 2018 – The FDA has granted a priority review to a supplemental new drug application (sNDA) for eltrombopag for use in combination with standard immunosuppressive therapy as a frontline treatment for patients with severe aplastic anemia (SAA), according to Novartis, the manufacturer of the oral thrombopoietin-receptor agonist. The designation is based on a Novartis analysis of results from research conducted by the National Heart, Lung and Blood Institute of the … (leggi tutto)